{"product_id":"blco-ansoff-analysis","title":"(BLCO) Bausch + Lomb Corporation ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Bausch + Lomb Corporation Ansoff Matrix Analysis helps you quickly assess growth options across market penetration, market development, product development, and diversification in a single structured framework; the page already includes a real preview\/sample so you can judge style and substance before buying—purchase the full version to get the complete ready-to-use analysis. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContact lens mix depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb posted about $4.8 billion in 2024 net sales, and its contact lens line spans daily disposables, biweekly, and monthly wear. That breadth matters because the company can sell more SKUs into the same optometry channel and deepen share with existing wearers. In a mature category, market penetration comes from adding users and lifting replacement volume, not just adding new products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCare-product attach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s Vision Care\/Consumer Health line includes contact lens care, so one lens buyer can also buy solution, drops, and cases. That lifts recurring spend from the same user and grows wallet share without new-market entry. The strategy fits a mature category where repeat use matters more than one-time sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTC eye-drop share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s OTC eye-drop line targets allergies, conjunctivitis, and dry eye, all mature retail and pharmacy categories where shelf space and repeat purchase drive share. Dry eye alone affects millions of adults, so even small gains in visibility can lift volume fast. Penetration here means winning more facings, stronger pharmacy placement, and higher refill rates in the same markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOphthalmic script gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb Corporation can lift ophthalmic script gains by winning more prescriptions in glaucoma, ocular hypertension, and retinal disorders, where demand already exists. In 2025, its net sales were about $4.8 billion, so even small share gains in established therapy areas can move revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets current physician demand.\u003c\/li\u003e\n\u003cli\u003eSells branded and generic drugs.\u003c\/li\u003e\n\u003cli\u003eFocuses on repeat prescriptions.\u003c\/li\u003e\n\u003cli\u003eUses existing treatment markets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSurgical case density\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s Surgical case density strategy pushes more cataract and vitreoretinal procedures through the same hospital and ASC accounts, using IOLs, phaco systems, and specialty instruments. Because these tools are reused across cases, higher procedure volume lifts installed-base utilization and deepens share of wallet. In fiscal 2025, this is the cleanest penetration lever: more cases, same accounts, more recurring supply pull.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrow share in existing surgery centers\u003c\/li\u003e\n\u003cli\u003eRaise installed-base utilization\u003c\/li\u003e\n\u003cli\u003eIncrease recurring instrument and consumable use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb Grows by Selling More to Existing Eye-Care Customers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb’s market penetration leans on its 2025 net sales of about $4.8 billion and a deep eye-care base. The play is to sell more lenses, solutions, drops, and surgical consumables into the same doctors, pharmacies, and surgery centers. More repeat use in existing channels, not new markets, drives the lift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLever\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003ePenetration effect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVision Care\u003c\/td\u003e\n\u003ctd\u003eDaily, biweekly, monthly lenses\u003c\/td\u003e\n\u003ctd\u003eMore SKUs per patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health\u003c\/td\u003e\n\u003ctd\u003eOTC drops and care\u003c\/td\u003e\n\u003ctd\u003eHigher refill rates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical\u003c\/td\u003e\n\u003ctd\u003eCataract and vitreoretinal cases\u003c\/td\u003e\n\u003ctd\u003eMore use per account\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps out Bausch + Lomb Corporation’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Bausch + Lomb Ansoff Matrix to quickly ease growth-strategy planning and decision fatigue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, reputable sources that validate each Ansoff growth path for Bausch + Lomb, speeding due diligence and making strategy assumptions traceable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal lens rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation can push its existing contact-lens portfolio into new countries, which is classic market development for Vision Care. The company already sells in global eye-health markets, so the core product set can stay the same while distribution and approvals expand by geography. In fiscal 2025, that strategy can lift revenue with lower R\u0026amp;D spend than a new product launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail channel expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation can drive market development by expanding OTC eye drops and nutritional supplements into more pharmacy, mass-retail, and self-care shelves. This fits how consumers already buy basic eye care: fast, frequent, and without a specialist visit. It is broader distribution, not a new product launch, so the upside comes from reach and shelf share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic lens reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTherapeutic contact lenses can move beyond core eye-care channels into more ophthalmology and post-operative care settings, so Bausch + Lomb Corporation can sell to more clinical buyers without changing the product. The opportunity is real: the WHO says 2.2 billion people have vision impairment or blindness, and cataract surgery alone remains a major global driver of post-op care. Wider use in surgery centers, hospitals, and specialist clinics can broaden access and lift clinical adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialist network growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialist network growth can widen Bausch + Lomb Corporation’s prescription ophthalmics reach by adding physician groups and specialty clinics, so the same medicines can be prescribed to more patients. That matters in a market where vision impairment affects about 2.2 billion people worldwide, according to the World Health Organization, leaving large unmet demand for eye care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore prescribers, same products\u003c\/li\u003e\n\u003cli\u003eBroader access to specialty clinics\u003c\/li\u003e\n\u003cli\u003eLarger addressable pharma market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational surgery access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb Corporation can expand International surgery access by placing IOLs, phacoemulsification systems, and surgical tools into more cataract and retinal centers across high-growth markets. Global cataract surgery volumes are above 28 million cases a year, so access gains can scale fast where hospitals already have OR capacity.\u003c\/p\u003e\n\u003cp\u003eAdoption still hinges on center access, surgeon training, and procurement ties, since many systems buy through long contracts and local distributors. This is market development, not new product design: the same surgical portfolio moves into new countries and more care channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus on cataract-heavy markets.\u003c\/li\u003e\n\u003cli\u003ePair devices with surgeon training.\u003c\/li\u003e\n\u003cli\u003eWin distributor and tender access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb Can Scale Vision Care and Surgery Across New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation can grow Vision Care and Surgical sales by moving the same products into more countries, clinics, and pharmacy chains. In fiscal 2025, that means scale over R\u0026amp;D: the WHO cites 2.2 billion people with vision impairment, and cataract surgery tops 28 million cases a year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMarket development lever\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVision Care\u003c\/td\u003e\n\u003ctd\u003e2.2 billion people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgery\u003c\/td\u003e\n\u003ctd\u003e28 million+ cataract cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy\u003c\/td\u003e\n\u003ctd\u003eNew markets, same products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBausch + Lomb Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew lens formats\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb’s product development in new lens formats means upgrading its daily disposable and frequent-replace lines with new materials, edge designs, and moisture features for existing wearers. In FY2025, contact lens franchise innovation mattered because it helps keep customers inside a portfolio that supports Bausch + Lomb’s roughly $4.8 billion net sales base. New comfort-led formats can lift repeat use and reduce churn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDry-eye innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation can extend its dry-eye platform by improving OTC drops for the same consumers already using artificial tears and by adapting pharma know-how from ocular disease care. Dry eye is a large, repeat-use category, so even small gains in relief time, comfort, or preservative-free tolerability can matter. This is product development, not a new market, and it fits the company’s eye-care base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEye-disease therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s eye-disease therapies support product development by adding proprietary and generic prescription options for glaucoma, ocular hypertension, and retinal disorders. This matters in a market where glaucoma affects about 80 million people worldwide, so even small gains in therapy breadth can lift specialist share. New treatments deepen the portfolio for the same prescribers and help strengthen the pharma franchise in current disease categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIOL platform upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s Surgical segment already sells intraocular lenses and delivery systems, so IOL platform upgrades fit product development in the same cataract market. New lens designs can lift visual outcomes, broaden surgeon choice, and refresh a mature franchise without changing the customer base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, better IOL design\u003c\/li\u003e\n\u003cli\u003eImproves outcomes and choice\u003c\/li\u003e\n\u003cli\u003eClassic product renewal move\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEquipment refinement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhacoemulsification systems and surgical instruments are already core Bausch + Lomb Corporation offerings, so equipment refinement is a low-risk product development move. Upgrades that speed setup, sharpen control, and cut procedure time can lift workflow in hospitals and ambulatory surgery centers, where repeat use drives recurring demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuild on core cataract surgery tools\u003c\/li\u003e\n\u003cli\u003eUpgrade workflow and procedure performance\u003c\/li\u003e\n\u003cli\u003eSupport repeat hospital and ASC orders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb Bets on Small Upgrades for Big Revenue Gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s product development centers on new lens, dry-eye, glaucoma, and surgical upgrades for the same customer base. In FY2025, its roughly $4.8 billion net sales base shows why small gains in comfort, outcomes, and workflow can matter. Glaucoma affects about 80 million people worldwide, so therapy breadth still counts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales base\u003c\/td\u003e\n\u003ctd\u003e$4.8 billion FY2025\u003c\/td\u003e\n\u003ctd\u003eProtects repeat revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma\u003c\/td\u003e\n\u003ctd\u003e80 million global cases\u003c\/td\u003e\n\u003ctd\u003eSupports therapy expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContact lenses\u003c\/td\u003e\n\u003ctd\u003eDaily and frequent-replace lines\u003c\/td\u003e\n\u003ctd\u003eDrives retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEye supplements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s eye supplements are related diversification: they move the Company beyond lenses into consumer wellness while staying inside eye health. The AREDS2 formula is linked to a 25% lower risk of progression to advanced age-related macular degeneration in high-risk patients, which helps reach a broader self-care audience than contact-lens users alone. That widens wallet share and supports cross-sell.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTherapeutic contact lenses move Bausch + Lomb Corporation beyond vision correction into post-operative care and medical therapy, so the buyer set shifts from retail consumers to surgeons and clinics. That diversification matters in a global eye-health market worth tens of billions of dollars, with the company’s 2025 filing still showing a multi-billion-dollar revenue base. It reduces reliance on consumer optics and ties growth to treatment-led demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s prescription pharma push is diversification: it moves into 3 specialist-led markets—glaucoma, ocular hypertension, and retinal disorders.\u003c\/p\u003e\n\u003cp\u003eThese drugs sell through prescribers, not retail contact-lens channels, so the company is adding a new product-market combination with different buying behavior and clinical access.\u003c\/p\u003e\n\u003cp\u003eThat shift raises mix complexity, but it also broadens the revenue base beyond lens sales and puts Bausch + Lomb in higher-value ophthalmic care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSurgical platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s surgical platform, led by surgical IOLs, phacoemulsification systems, and instruments, sells into hospitals and ambulatory surgery centers, so it is tied to procedure volume and capital budgets, not just consumer refill demand. In 2025, the company reported about $4.8 billion in net sales, and this mix helps widen revenue beyond vision-care consumables.\u003c\/p\u003e\n\u003cp\u003eThis is classic diversification in the Ansoff Matrix: it adds adjacent surgical products to an existing eye-care base and deepens access to higher-value operating-room customers. One surgery can pull through lenses, equipment, and tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets hospital and ASC buyers\u003c\/li\u003e\n\u003cli\u003eDepends on procedure demand\u003c\/li\u003e\n\u003cli\u003eReduces reliance on replenishment sales\u003c\/li\u003e\n\u003cli\u003eExtends Bausch + Lomb beyond consumables\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-segment portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb’s three-segment model spans Vision Care\/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical, so its diversification reaches consumer, clinical, and operative eye-health demand. That mix lowers reliance on one product cycle and widened 2025 revenue streams across recurring contact-lens care, prescription therapies, and procedures. In 2025, net sales were about $4.8 billion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsumer, clinical, and surgical exposure\u003c\/li\u003e\n\u003cli\u003eReduces single-market dependence\u003c\/li\u003e\n\u003cli\u003eSupports steadier cash flow mix\u003c\/li\u003e\n\u003cli\u003e2025 net sales: about $4.8 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb Broadens Beyond Lenses Into Higher-Value Eye Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification is Bausch + Lomb Corporation’s move from lenses into eye supplements, therapeutic contact lenses, prescription drugs, and surgery. In 2025, net sales were about $4.8 billion, so this mix spread demand across consumer, specialist, and hospital channels. It lowers dependence on contact-lens replenishment and adds higher-value clinical revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplements\u003c\/td\u003e\n\u003ctd\u003eConsumers\u003c\/td\u003e\n\u003ctd\u003eAdjacency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRx drugs\u003c\/td\u003e\n\u003ctd\u003ePrescribers\u003c\/td\u003e\n\u003ctd\u003eNew channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgery\u003c\/td\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eHigher value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234115526921,"sku":"blco-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/blco-ansoff-matrix.webp?v=1785713174","url":"https:\/\/dcfanalyst.com\/products\/blco-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}